Company profile for Cabaletta Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that are designed to precisely ablate specific autoantibody-producing B cells while sparing normal antibody-producing B cells that protect the body from infection. C...
Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that are designed to precisely ablate specific autoantibody-producing B cells while sparing normal antibody-producing B cells that protect the body from infection. CAAR T cells are based on the revolutionary chimeric antigen receptor (CAR) T cell technology developed at the University of Pennsylvania that resulted in one of the first commercially-available CAR T cell therapies.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
150 N Radnor Chester Rd Suite F-200 Radnor, PA 19087
Telephone
Telephone
+1 610 977 2422
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Clinical Outsourcing

Clinical Outsourcing

Not Confirmed

envelop Contact Supplier

Clinical Outsourcing

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2026/02/24/3243502/0/en/Cabaletta-Bio-to-Participate-in-the-TD-Cowen-46th-Annual-Health-Care-Conference.html

GLOBENEWSWIRE
24 Feb 2026

https://www.globenewswire.com/news-release/2026/02/05/3232923/0/en/Cabaletta-Bio-to-Participate-in-the-Guggenheim-Emerging-Outlook-Biotech-Summit-2026.html

GLOBENEWSWIRE
05 Feb 2026

https://www.pharmiweb.com/press-release/2026-01-12/ind-amendment-clearance-obtained-for-clinical-manufacturing-of-rese-cel-from-cabaletta-bio-using-cel

PHARMIWEB
12 Jan 2026

https://www.globenewswire.com/news-release/2026/01/12/3216791/0/en/Cabaletta-Bio-Announces-2026-Strategic-Priorities.html

GLOBENEWSWIRE
12 Jan 2026

https://www.globenewswire.com/news-release/2025/11/10/3184437/0/en/Cabaletta-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/11/04/3180242/0/en/Cabaletta-Bio-to-Participate-in-Upcoming-Investor-Conferences-in-November-and-December.html

GLOBENEWSWIRE
04 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty